Manhattan, New York-based Global investment firm KKR announced a commitment of approximately $200 million to deepen its presence in India’s rapidly growing medical devices industry. This investment is being channeled primarily through Healthium MedTech, KKR’s India-based medical device platform, which it had acquired last year for roughly $840 million.
Key Objectives of the Investment:
- Expansion: KKR is using a “bolt-on strategy,” proactively seeking to acquire scalable and profitable assets to merge under Healthium. The goal is to strengthen and complement Healthium’s existing portfolio.
- Focus Areas: The capital will be used to bolster the product base in key areas such as surgical consumables, wound closure, orthopedics, and advanced medical technology solutions. The firm is specifically keen on entering new therapy areas such as cardiology, orthopedics, and diagnostics.
- Growth Support: The investment will support the expansion of domestic manufacturing, fund further acquisitions, and aid in the development of export capabilities.
This renewed focus on India’s medical technology sector underscores KKR’s long-term conviction, following earlier successful exits in the sector, and adds to its broader healthcare portfolio in India, which includes companies such as JB Chemicals and Pharma, Max Healthcare, Healthcare Global Enterprises (HCG), and Gland Pharma.
Last updated: December 26th, 2025
